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Immunologically humanized mice are promising tools to
analyze in vivo human anit-tumor immune responses.
When human PBMCs are transferred into NOG (NOD/
Shi-scid IL2rgnull) mice, severe GVHD developed in a
couple of weeks hinders long term detailed analysis of
human immune responses. In this study, we developed
novel MHC class I and class II-deficient NOG mice, and
characterized the reconstituted human immune systems
in the mice after inoculation of human PBMC. NOG
mice with no murine MHC class I and class II were
generated by knockout of b2-microglobulin gene, a
component of MHC class I molecule, and IAb, the light
chain of the class II IA (NOG-dKO; NOG-b2m, IAb
double KO mouse). Administration of human PBMC
into NOG-dKO (huNOG-dKO) mice induced mild
GVHD, but its severity was much less than that
occurred in control NOG mice in spite of sufficient
engraftment of human immune cells, when evaluated by
decrease of body weight and survival as well as human
T cell infiltration in various organs. Various types of
human immune cells were detected in the peripheral
blood of NOG-dKO until day14 (DC and naïve T cells),
day21 (NKT cells), day35 (NK cells), or more than
day100 (T cells and B cells). Immunization with an inac-
tivated influenza vaccine resulted in the increase of
serum influenza-specific human IgG Ab along with
increases of influenza-specific Ab producing B cells in
the spleens, indicating the induction of antigen specific
B cells in the huNOG-dKO. Immunization with human
monocyte-derived dendritic cells (DC) pulsed with
HLA-A2 restricted CMV peptide (CMVpp65) induced
CMVpp65-specific CTLs in spleens, bone marrows, and
peripheral blood, indicating the induction of antigen
specific T cells in the huNOG-dKO. When activated
human peripheral blood T cells transduced with TCR
specific for melanoma antigen MART-1, were trans-
ferred into NOG-dKO and NOG mice implanted with
human melanoma cell lines, stronger tumor growth
inhibition was observed in the NOG mice along with
more increased transferred T cells due to xenogenic
GVHD responses than the NOG-dKO mice, and the
NOG mice died in 4-8 weeks. However, administration
of human recombinant IL2 into the NOG-dKO mice
resulted in enhanced anti-tumor effects without any sign
of GVHD accompanied by prolonged survival of T cells
containing higher MART-1/HLA-A2 tetramer positive
cells, indicating more detailed analysis of anti-tumor
immune responses is possible using NOG-dKO mice.
Therefore, NOG-dKO mice are useful tools for more
detailed analysis of both induction and effector phases
of T cell and B cell responses for human tumor immu-
nology research.
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